Health-economic evaluation of risdiplam (Evrysdi®) in patients with spinal muscular atrophy

Health-economic evaluation of risdiplam (Evrysdi®) in patients with spinal muscular atrophy

Background. Spinal muscular atrophies (SMA) are clinically and genetically heterogenous inherited orphan diseases leading to progressive spinal motoneurons degeneration and loss of function. Risdiplam and nusinersen are both authorized in Russia for pathogenic SMA treatment and included in the list...

Full description

Bibliographic Details
Main Authors: А. S. Kolbin, А. А. Kurylev, Yu. Е. Balykina, М. А. Proskurin, S. А. Mishinova
Format: Article
Language:Russian
Published: IRBIS LLC 2021-01-01
Series:Фармакоэкономика
Subjects:
spinal muscular atrophy
health-economic evaluation
medical costs
Online Access:https://www.pharmacoeconomics.ru/jour/article/view/511

Similar Items

Similar Items